Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets

Qing Lv, Qiuxia Li, Peizhuo Zhang, Yingjuan Jiang, Xinwei Wang, Qiujing Wei, Shuangyan Cao, Zetao Liao, Zhiming Lin, Yunfeng Pan, Jianlin Huang, Tianwang Li, Ou Jin, Yuqiong Wu, Jieruo Gu, Qing Lv, Qiuxia Li, Peizhuo Zhang, Yingjuan Jiang, Xinwei Wang, Qiujing Wei, Shuangyan Cao, Zetao Liao, Zhiming Lin, Yunfeng Pan, Jianlin Huang, Tianwang Li, Ou Jin, Yuqiong Wu, Jieruo Gu

Abstract

Background: MicroRNAs can potentially regulate every aspect of cellular activity. In this study, we investigated whether AS pathogenesis involves microRNAs disorders.

Result: The expression of 2 microRNAs, hsa-miR-126-3p and hsa-miR-29a, was significantly lower in active AS group before etanercept therapy than in control group. Marched fold changes of them were 3.76 and 16.22. Moreover, expressions of hsa-miR-126-3p and hsa-miR-29a were dramatically upregulated after 12-weeks etanercept treatment. Fold changes were 2.20 and 3.18. All regulations of microRNAs expression mentioned before were statistically significant (fold change >2 and P < 0.05). The expression disorders of the 2 microRNAs did not statistically significantly correlated with BASDAI, CRP, and ESR.

Conclusion: AS pathogenesis involved dysregulation of microRNAs. Hsa-miR-126-3p and hsa-miR-29a will probably become the potential biomarkers and provocative therapeutic targets of AS.

Figures

Figure 1
Figure 1
Calibrated fluorescence intensity of microarray in different groups. (a) The microRNAs signal intensity of AS group was compared with that of healthy control. There were 31 microRNAs in this figure. 26 of them, at the left side of the figure, expressed significantly higher in AS group than in HC. The other 5, at the right side of the figure, were probably higher in AS group than in control group. (b) The microRNAs signal intensity of AS group before and after etanercept therapy was compared. There were 36 microRNAs in this figure. 23 of them, at the left side of the figure, had definite expression regulation after therapy. Among them, the expression levels of 6 downregulated significantly after regular etanercept therapy, while 17 upregulated. However, the other 13 microRNAs, at the right side of the figure, were thought to keep different expression levels, not so dramatically changed in AS group before and after etanercept therapy. 7 among them downregulated, while 6 upregulated. AS, ankylosing spondylitis; HC, healthy control.
Figure 2
Figure 2
Nine microRNAs had higher expressed levels in AS group than healthy control group, and the expression levels of them downregulated after regular etanercept therapy for 12 weeks. The calibrated signal ratio of AS group before therapy to healthy control group were >3 : 1, and the ratio of AS group after therapy to before therapy were

Figure 3

Figure 3

Figure 3
Figure 3
Figure 3

References

    1. Thomas G. P., Brown M. A. Genetics and genomics of ankylosing spondylitis. Immunological Reviews. 2010;233(1):162–180. doi: 10.1111/j.0105-2896.2009.00852.x.
    1. Brown M. A., Kennedy L. G., MacGregor A. J., et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis and Rheumatism. 1997;40(10):1823–1828. doi: 10.1002/art.1780401015.
    1. Caffrey M. F., James D. C. Human lymphocyte antigen association in ankylosing spondylitis. Nature. 1973;242(5393):p. 121. doi: 10.1038/242121a0.
    1. Brewerton D. A., Hart F. D., Nicholls A., Caffrey M., James D. C. O., Sturrock R. D. Ankylosing spondylitis and HL-A 27. The Lancet. 1973;301(7809):904–907. doi: 10.1016/S0140-6736(73)91360-3.
    1. Schlosstein L., Terasaki P. I., Bluestone R., Pearson C. M. High association of an HL-A antigen, W27, with ankylosing spondylitis. The New England Journal of Medicine. 1973;288(14):704–706. doi: 10.1056/NEJM197304052881403.
    1. Brown M. A., Kennedy L. G., Darke C., et al. The effect of HLA-DR genes on susceptibility to and severity of ankylosing spondylitis. Arthritis & Rheumatology. 1998;41(3):460–465.
    1. Ambros V. MicroRNAs: tiny regulators with great potential. Cell. 2001;107(7):823–826. doi: 10.1016/S0092-8674(01)00616-X.
    1. Lewis B. P., Burge C. B., Bartel D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. doi: 10.1016/j.cell.2004.12.035.
    1. Huang Y., Shen X. J., Zou Q., Wang S. P., Tang S. M., Zhang G. Z. Biological functions of microRNAs: a review. Journal of Physiology and Biochemistry. 2011;67(1):129–139. doi: 10.1007/s13105-010-0050-6.
    1. Murata K., Yoshitomi H., Tanida S., et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Research and Therapy. 2010;12(3, article R86) doi: 10.1186/ar3013.
    1. Tang Y., Luo X., Cui H., et al. MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis and Rheumatism. 2009;60(4):1065–1075. doi: 10.1002/art.24436.
    1. Glinsky G. V. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. Cell Cycle. 2008;7(16):2570–2583. doi: 10.4161/cc.7.16.6524.
    1. Huang C.-H., Wei J. C.-C., Chang W.-C., et al. Higher expression of whole blood microRNA-21 in patients with ankylosing spondylitis associated with programmed cell death 4 mRNA expression and collagen cross-linked C-telopeptide concentration. Journal of Rheumatology. 2014;41(6):1104–1111. doi: 10.3899/jrheum.130515.
    1. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. Journal of Rheumatology. 1994;21(12):2286–2291.
    1. Lee R. C., Feinbaum R. L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854. doi: 10.1016/0092-8674(93)90529-Y.
    1. Bartel D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi: 10.1016/S0092-8674(04)00045-5.
    1. van Rooij E., Olson E. N. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. Journal of Clinical Investigation. 2007;117(9):2369–2376. doi: 10.1172/JCI33099.
    1. Mitchell P. S., Parkin R. K., Kroh E. M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(30):10513–10518. doi: 10.1073/pnas.0804549105.
    1. Chen X., Ba Y., Ma L., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Research. 2008;18(10):997–1006. doi: 10.1038/cr.2008.282.
    1. Wang K., Zhang S., Marzolf B., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(11):4402–4407. doi: 10.1073/pnas.0813371106.
    1. Ji X., Takahashi R., Hiura Y., Hirokawa G., Fukushima Y., Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clinical Chemistry. 2009;55(11):1944–1949. doi: 10.1373/clinchem.2009.125310.
    1. Zhu W., Qin W., Atasoy U., Sauter E. R. Circulating microRNAs in breast cancer and healthy subjects. BMC Research Notes. 2009;2, article 89 doi: 10.1186/1756-0500-2-89.
    1. Heneghan H. M., Miller N., Lowery A. J., Sweeney K. J., Kerin M. J. MicroRNAs as novel biomarkers for breast cancer. Journal of Oncology. 2009;2009:7. doi: 10.1155/2010/950201.950201
    1. Kim V. N., Nam J.-W. Genomics of microRNA. Trends in Genetics. 2006;22(3):165–173. doi: 10.1016/j.tig.2006.01.003.
    1. Ogawa T., Iizuka M., Sekiya Y., Yoshizato K., Ikeda K., Kawada N. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochemical and Biophysical Research Communications. 2010;391(1):316–321. doi: 10.1016/j.bbrc.2009.11.056.
    1. van Rooij E., Sutherland L. B., Thatcher J. E., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(35):13027–13032. doi: 10.1073/pnas.0805038105.
    1. Oglesby I. K., Bray I. M., Chotirmall S. H., et al. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. Journal of Immunology. 2010;184(4):1702–1709. doi: 10.4049/jimmunol.0902669.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit